Guardant Health, Inc. GH
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
4/9
Piotroski F — financial health
-2.57
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $982.0M | -$416.3M | — | -$233.1M | -$99.3M |
| 2024 | $739.0M | -$436.4M | — | -$274.9M | -$139.6M |
| 2023 | $563.9M | -$479.4M | — | -$345.5M | $158.7M |
| 2022 | $449.5M | -$654.6M | — | -$386.9M | $60.2M |
| 2021 | $373.7M | -$384.8M | — | -$284.1M | $645.0M |
| 2020 | $286.7M | — | — | -$140.1M | $1.3B |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.57 (distress)
- Working capital / assets 0.578
- Retained earnings / assets -1.487
- EBIT / assets -0.217
- Equity / liabilities -0.047
Source: SEC EDGAR filings · CIK 0001576280 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.